Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Share S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC

Sign up to save your podcasts

S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC

S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC

More shows like OncLive® On Air

Hematologic Oncology Update

Journal of Clinical Oncology (JCO) Podcast

Research To Practice | Oncology Videos

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

The New Yorker Radio Hour

ASCO Daily News

The Daily

OncoPharm

ASCO Guidelines

Lung Cancer Considered

Oncology Today with Dr Neil Love

CCO Oncology Podcast

The Ezra Klein Show

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions